Smallpox
The FDA updated its informational overview regarding smallpox, defining it as a highly contagious and potentially fatal infectious disease with no specific treatment, emphasizing that vaccination is the sole method of prevention.
This information affects manufacturers of smallpox vaccines, clinical researchers in the infectious disease sector, and regulatory professionals managing biologics portfolios.
The source reiterates the critical nature of smallpox as a public health threat and confirms that the regulatory landscape for this disease remains focused exclusively on preventative biological interventions rather than therapeutic treatments. This suggests a continued high bar for safety and efficacy in the development and maintenance of vaccine products.
Regulatory and clinical teams should maintain oversight of vaccine portfolios and ensure that any new developments align with the established medical consensus that vaccination remains the primary preventative measure for smallpox.
Smallpox is a serious, highly contagious, and sometimes fatal infectious disease. There is no specific treatment for smallpox disease, and the only prevention is vaccination. The name is derived from the Latin word for "spotted" and refers to the raised bumps that appear on the face and body of an i
Open in openFDA / FDA.gov